NewsOver 750 Novel Food Applications Submitted To FSA -...

Over 750 Novel Food Applications Submitted To FSA – But Only 200-Plus Currently Moving Forward

-

NERVOUS times for many in the CBD industry this evening as the UK Food Standards Agency (FSA) has released numbers to BusinessCann on Novel Food applications.

Yesterday (March 31), was the deadline for applicants to file Novel Food submissions to the FSA – following some earlier delays; see here.

The FSA this evening confirmed that it has received over 750 CBD applications – predominantly from bulk ingredient suppliers – since January 1, this year. 

It went on to say that over 200 applications are currently undergoing Administration, and or Validation checks and that two have passed Validation – one of these is synthetic CBD firm Pureis CBD, as reported earlier.

Which leaves some 550 applications in the system and this is what the FSA is saying on these this evening:

‘Those applications not going through administration/validation checks or not validated will either be:

In progress – a form has been submitted but the applicant is still within the seven day-window all applicants have to submit their supplementary documents

-Incomplete applications

-Withdrawn applications

What Does This All Mean?

Well, the last update we had from the FSA on numbers was on March 1, when it revealed that 404 applications – it refers to these as ‘regulated product applications’ – had been received 

It went on to say that 89 of these have ‘passed the initial Administrative check’ allowing the to pass on to Validatuon and 138 – over one-third – ‘have been assessed and not passed the Admin check’. 

Today’s figures reflect the same pattern and that effectively leaves a whole lot of applicants facing exclusion from the UK CBD market. 

Later this month, although more likely in May, the FSA will publish details on the businesses and products who have passed the Validation stage of the Novel Food process.

Those CBD business – whether wholesalers or retailers who are not on this list – face the threat of having their products withdrawn from the market.

However, in the last week-or-so the FSA has adopted a less Draconian stance saying it will allow businesses who have not been able to demonstrate adherence to its strict guidelines on Validation more time to comply.

For all the background to this – and to stay in touch with future happenings in the fast-growing UK CBD sector stay tuned to www.businesscann.com 



Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Thought Leaders Acquisition Of mellow Set To Accelerate Growth Across UK, Europe, And Asia Footprint

THE CBD world is set with a massive shake-up this week as Thought Leaders, the US cannabis & CBD investment company,...

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council have been identified following a special general meeting attended by...

CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing

Chartered Psychologist and Head of Research at Drug Science, Dr Anne Katrin Schlag, heads up the newly formed Cannabis...

European Cannabis Market Leader Bloomwell Group Secures $10m Investment

The Bloomwell Group has successfully closed a seed funding round of over $10 million dollars—the highest publicly known seed investment...

German Hemp Farm Numbers Up 900% In Seven Years – As industry Calls For Post-Election Reform

THE number of German farms growing industrial hemp has hit 863 – the highest figure since the federal republic...

US Company Set To Launch UK Medical Cannabis Study In Partnership With Manchester University

A GROUND-BREAKING human pilot study centred on the University of Manchester could provide answers to using cannabis as a...

Must read

Medical Cannabis Cost-Benefit Analysis Set To Be Launched By UK CIC At A Cost of £30,000

THE initial priorities of the UK Cannabis Industry Council...

CIC Research Group Looking To Overcome The ‘Scandalous’ Impasse On UK Medical Cannabis Prescribing

Chartered Psychologist and Head of Research at Drug Science,...

You might also likeRELATED
Recommended to you